PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- China Biopharma, Inc. , a biopharmaceutical company focused on developing and distributing human vaccine products in China, announced today that the Company will present at the 4th Annual PIPEs Conference 2006 being held in New York City at the Waldorf-Astoria Hotel on November 7 and 8, 2006.
Chairman and CEO of China Biopharma, Inc., Peter Wang, will present on Tuesday, November 7 at 10:30 am and 3:30 pm in the Metropolitan East room; and on Wednesday at 9:00 am in Gramercy room. Mr. Wang will provide an overview of the company, its competitive strengths in the Chinese vaccination market, target acquisitions and other significant growth strategies.
The PIPEs Conference is touted as the largest small cap event on Wall Street, with an expected audience of more than 1,000 financial professionals, including institutional investors, investment bankers, financial analysts and members of the media. The PIPEs Conference offers unmatched education and networking, with experts in the fields of structured finance, private placements, and small cap stock investing. For more information or to register, visit http://www.dealflowmedia.com/conferences/pipesconf.html.
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, Zhejiang Tianyuan Biotech Co., Ltd. and Hainan CITIC Biopharmaceutical Development Co., Ltd., the Company develops and distributes human vaccine products throughout the world's most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international vaccine providers, China Biopharma is building a highly- competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.com.cn.
Safe Harbor Statement
Some of the statements made in this press release discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
CONTACT: At the Company: George Ji China Biopharma, Inc. Tel: +1 (609) 651-8588 ir@chinabiopharma.nethttp://www.chinabiopharma.com.cn Investor Relations: OTC Financial Network Peter Clark Tel: +1 (781) 444-6100x629 peter@otcfn.comhttp://www.otcfn.com/cbpc
China Biopharma Inc.
CONTACT: George Ji of China Biopharma, Inc., +1-609-651-8588,ir@chinabiopharma.net; or Investor Relations: Peter Clark of OTC FinancialNetwork, +1-781-444-6100 ext. 629, peter@otcfn.com
Web site: http://www.chinabiopharma.com.cn//
